A total of 6377 patients were analyzed (pRCC type I n = 469, pRCC type II n = 473 and ccRCC n= 5435). MVA revealed that increasing tumor size (OR 1.225, p < 0.001), pRCC type I vs. ccRCC (OR 0.482, p = 0.002), higher Fuhrman grade (OR 2.409, p = 0.009), lymphovascular invasion (OR 2.735, p = 0.018) and necrosis in pathology (OR 1.976, p = 0.035) were significant risk factors for cancer specific mortality (Table). KMS showed that OS rates in patients with pRCC type I, II and ccRCC were 82, 74 and 76% at 5 years and 72.5, 48, 60.3% at 10 years, respectively (p =0.001) (Figure below). CSS rates in patients with pRCC type I, II and ccRCC were 98, 90.6 and 86.6% at 5 years and 97.5, 78.3 and 79.5% at 10 years, respectively (p < 0.001) (Figure below).
The authors concluded that pRCC type II represents a higher risk than histopathological subtype pRCC Type I, with oncological outcomes comparable to ccRCC. More studies should be performed to address the increased risk of pRCC type 2.
Presented By: Ahmet Bindayi, La Jolla, CA, USA
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre Twitter: @GoldbergHanan at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA